Home›Companies›Healthcare›aMBR Genomics

aMBR Genomics, Inc.

Develops a noninvasive liquid biopsy platform for early cancer detection.

Updated Nov 10, 2026·Latest SEC filing Mar 31, 2026·Suggest an edit

About aMBR Genomics

aMBR Genomics is a private company based in Madison, Wisconsin, incorporated in 2025 in Delaware. It has reported $1,100,000 raised in one offering on Form D since March 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 21, 2025Mar 31, 2026$1,100,000of $2.0M target4$275KOptionsRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on aMBR Genomics's Form D filed Mar 31, 2026.

AS
Ahna Skop
President and director
MM
Michael Moser
Executive officer
EY
Eugene Yeo
Executive officer and director

Sources

  1. SECaMBR Genomics, Inc. filing history
  2. InvestorWisconsin Economic Development Corporation company page